Literature DB >> 3459724

Molecular analysis of HLA class I and class II antigen loss mutants reveals a homozygous deletion of the DR, DQ, and part of the DP region: implications for class II gene order.

H Erlich, J S Lee, J W Petersen, T Bugawan, R DeMars.   

Abstract

The mutant human B-lymphoblastoid cell lines, 721.174 and 721.180, previously reported to exhibit greatly reduced expression of human HLA class I and II antigens (DeMars et al., Hum Immunol 11:77, 1984), were analyzed by Southern blotting using class II cDNA and genomic clones as hybridization probes. All genomic sequences complementary to DR alpha, DR beta, DQ alpha, and DQ beta probes were absent from these mutants. DZ alpha genomic sequences were deleted as were the DP alpha 1 and DP beta 1 loci but the DP beta 2 and most, if not all, of the DP alpha 2 locus were retained. However, no RNA transcripts for either DP alpha 2 or DP beta 2 could be detected. The mapping of the deletion breakpoint within the DP cluster allows the orientation of the loci in the DP region with respect to the centromere as follows: centromere, DP beta 2, DP beta 1, DP alpha 1, (DQ, DR). In addition, the analysis of a set of DR-, DQ-, DP+ homozygous deletion mutants (721.82, 721.84, and 721.101) reveals a deletion breakpoint between the DQ alpha 1/DQ beta 1 loci and the DQ alpha 2/DQ beta 2 loci. These mutants retain DZ alpha genomic sequences, tentatively mapping the DZ alpha locus between the DQ and the DP region. The residual ability of the DR-, DQ-, DP- mutants (174 and 180)* to stimulate allogeneic and autologous lymphoproliferative responses must be attributed to expression of as yet unidentified class II antigens, or to non-class II antigens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459724     DOI: 10.1016/0198-8859(86)90049-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  22 in total

1.  A cDNA clone for a novel nuclear protein with DNA binding activity.

Authors:  T Mattioni; C R Hume; S Konigorski; P Hayes; Z Osterweil; J S Lee
Journal:  Chromosoma       Date:  1992-10       Impact factor: 4.316

2.  Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques.

Authors:  Shelby L O'Connor; Alex J Blasky; Chad J Pendley; Ericka A Becker; Roger W Wiseman; Julie A Karl; Austin L Hughes; David H O'Connor
Journal:  Immunogenetics       Date:  2007-03-24       Impact factor: 2.846

3.  Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation.

Authors:  Lars-Egil Fallang; Elin Bergseng; Kinya Hotta; Axel Berg-Larsen; Chu-Young Kim; Ludvig M Sollid
Journal:  Nat Immunol       Date:  2009-08-30       Impact factor: 25.606

4.  An unusual form of alternative splicing in the HLA-DNA gene.

Authors:  S Rosen-Bronson; E O Long
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

Review 5.  Genetics of HLA class II regulation.

Authors:  C R Hume; J S Lee
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 6.  Selection of the MHC class II-associated peptide repertoire by HLA-DM.

Authors:  S O Arndt; A B Vogt; G J Hämmerling; H Kropshofer
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 7.  Organization of the human class I major histocompatibility complex genes.

Authors:  B H Koller; D Geraghty; H T Orr; Y Shimizu; R DeMars
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

8.  Endogenous retroviral long terminal repeats within the HLA-DQ locus.

Authors:  S Kambhu; P Falldorf; J S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  A novel HLA class II molecule.

Authors:  N Fernandez; M O Labeta; H Festenstein
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

10.  Sequence analysis of HLA class II domains: characterization of the DQw3 family of DQB genes.

Authors:  A Hiraiwa; C E Seyfried; G T Nepom; E C Milner
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.